A comparison of the sensitivity of APPT reagents to the effects of enoxaparin, a low-molecular weight heparin

Pathology

Volumn 33, Issue 3, 2001, Pages 347-352

  Ip, Beatrice K H ^a   Thomson, Amanda R ^a   Moriarty, Helen T ^b  

^a ANZAC Research Institute   (Australia)

^b CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Anti Xa; APTT; Enoxaparin; LMWH

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; NADROPARIN; REAGENT; TINZAPARIN; ANTICOAGULANT AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC ACCURACY; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; ANIMAL; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; EVALUATION; FEMALE; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTICOAGULANTS; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; INDICATORS AND REAGENTS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; SENSITIVITY AND SPECIFICITY;

EID: 0034742540     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313020126304     Document Type: Article

References (45)

1. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
2. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin
3. Editorial: Standardisation of APTT reagents for heparin therapy monitoring: Urgent or fading priority?
4. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin)
5. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement
6. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
7. Rationale for development of low molecular weight heparins and their clinical potential in the prevention of postoperative venous thrombosis
8. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin
9. Therapeutic use of low molecular weight heparins: Knowledge to date and their application to therapy
10. Treatment of venous thromboembolism
11. Effectiveness and safety of low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE)
12. Drag therapy: Low molecular weight heparins
13. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: A metaanalysis
14. Treatment of deep vein thrombosis with low molecular weight heparins
15. Treatment of deep vein thrombosis: Is thrombosis regression a desirable endpoint?
16. Annotation: Low molecular weight heparin(s)
17. Heparin anticoagulation
18. Pharmacology of low molecular weight heparins
19. The new heparins
20. Interactions of heparins in vascular environment
21. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins
22. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits
23. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
24. Low molecular weight heparins: Pharmacology and clinical applications
25. Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood
26. International committee communications: Partial thromboplastin time test - Proposed performance guidelines
27. Monitoring of heparin therapy with the activated partial thromboplastin time and chromogenic substrate assays
28. The effects of heparin on the activated partial thromboplastin time of the college of American Pathologists survey specimens
29. Establishing a therapeutic range for heparin therapy
30. Laboratory monitoring of heparin therapy
31. Comparison of some activated partial thromboplastin test (APTT) reagents
32. Variability in heparin sensitivity of APTT reagents
33. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer
34. Monitoring heparin therapy: Relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples
35. Comparative evaluation of 17 commercial APTT reagents
36. The therapeutic range for heparin therapy: Relationship between six activated partial thromboplastin time reagents and two heparin assays
37. Synthetic phospholipid based activated partial thromboplastin time APTT reagents that replace traditional animal based reagents
38. Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: Usefulness for monitoring heparin therapy
39. Effect of clot detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT
40. Response of the activated partial thromboplastin time (APTT) to heparin is influenced by coagulometers
41. The APTT monitoring of heparin - The 1STH/ICSH collaborative study
42. Patient based ratios in the monitoring of therapeutic heparinisation by APTT
43. Strong lupus anticoagulant causes interference with heparin assay
44. Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration
45. Low molecular weight heparin therapy: Is monitoring needed?